ImmunityBio (IBRX) Stock Forecast & Price Target

ImmunityBio is well positioned because the FDA’s expansion of ANKTIVA into high-risk BCG-unresponsive papillary-only NMIBC materially broadens the addressable U.S. patient pool, which management cites as representing upwards of 60% of high-risk BCG-UR NMIBC patients, while earlier data showed 62% complete response and 58% of responders maintained CR for at least 12 months. The thesis is further strengthened by ASCO 2026, where ANKTIVA showed immune-restoration signals in NSCLC and favorable comparative durability in NMIBC, including 47.3% 12-month CR versus 18.8% for pembrolizumab and modeled DOR of 26.85 months versus 16.20 months. Beyond clinical momentum, exclusive U.S. rights to Tokyo-172 BCG and a potential January 6, 2027 PDUFA support a more self-reliant commercial platform, though execution, reimbursement, and capital needs remain key risks.

ImmunityBio is facing a meaningful regulatory overhang because the FDA continues to question single-arm evidence in papillary-only disease, where TURBT can independently generate a roughly 50% cure rate and obscure ANKTIVA’s incremental benefit. The agency’s stance in both its 2018 and updated 2024 guidance, reinforced by the refusal to accept non-randomized papillary data for JNJ’s SunRISe program, suggests that ImmunityBio may ultimately need more costly and time-consuming randomized evidence to support ANKTIVA + BCG. That concern weakens confidence in the durability and breadth of the company’s lead asset, especially since the sBLA acceptance communication still acknowledged issues with the QUILT 3.032 Cohort B single-arm design.